Posts by: Alice Melão

News

A Phase 1/2 clinical trial assessing a combination of AVEO Oncology’s tivozanib and Opdivo (nivolumab) as a treatment for advanced kidney cancer has entered the Phase 2 stage. With the Phase 1 ... Read more

June 16, 2017

Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows

News

A combination of varlilumab and Opdivo (nivolumab) stopped tumor growth in 80 percent of the 36 patients in a Phase 1 clinical trial, according to varlilumab’s developer, Celldex Therapeutics. Tumors shrank significantly in ... Read more

June 14, 2017

Early Trial Data Supports Keytruda as Standalone Therapy for Advanced Stomach Cancers

News

Results from a first group of patients in a Phase 2 clinical trial appear to support Keytruda (pembrolizumab) being used to treat people with advanced or recurrent gastic or gastroesophageal junction adenocarcinoma who ... Read more

June 12, 2017June 12, 2017

NANT Cancer Vaccine Clinical Trial Plans Expanding to Include Multiple Cancers

News

The NANT cancer vaccine program, being developed by NantKwest in collaboration with Nantworks, will be tested as a possible treatment for several other cancers in addition to pancreatic cancer, its initial target. ... Read more

May 26, 2017May 26, 2017

Rush Now Enrolling Patients in Phase 2 Trial Testing Opdivo Combo Therapies for Advanced Renal Cell Carcinoma

News

Chicago’s Rush University Medical Center is recruiting patients with advanced renal cell carcinoma for a Phase 2 trial to evaluate whether Opdivo (nivolumab) combined with other investigational immunotherapy drugs is more effective than the ... Read more

May 22, 2017

FDA Approves Keytruda as First- and Second-Line Therapy for Bladder Cancer

News

The U.S. Food and Drug Administration has approved Merck’s anti-PD1 therapy Keytruda (pembrolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, or bladder cancer. Keytruda was granted accelerated ... Read more

May 5, 2017

Screening Tool Approved to Monitor Immune Response to Immunotherapy in Cancer Patients

News

Cancer Genetics Incorporated announced today that its immuno-oncology (IO) assay, Complete::IO, received Clinical Laboratory Improvement Amendments (CLIA) validation and approval. This new screening tool is intended to provide a fast and accurate ... Read more

April 28, 2017April 28, 2017

PD-1 Expression in Immune T-cells Can Help Define Immunotherapy Strategies for Lung Cancer Patients

News

Researchers have found that blood levels of a subset of immune cells, called CD8+ T-cells, following immunotherapy targeting the PD-1 pathway can help determine the anti-tumor response of lung cancer patients. Their ... Read more

April 27, 2017

Latest Results Presented on ARMO’s Lead Immunotherapy Candidate, AM0010

News

Combining ARMO BioSciences‘ AM0010, or PEGylated Interleukin-10, with immune checkpoint inhibitors induces better objective response rates and disease control rates in kidney cancer patients, than any of the drugs alone, according to new data ... Read more

March 31, 2017

Non-mutation-based Cancer Gene Expression Is Promising Therapy Path, Professor Says

News

A better understanding of how cancer cells control their gene expression to turn on tumor-promoting pathways could help scientists identify vulnerabilities in the process that could lead to therapies. A professor ... Read more